cebranopadol Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Cebranopadol is an opioid analgesic of the benzenoid class which is currently under development internationally by Grünenthal, a German pharmaceutical company, and its partner Depomed, a pharmaceutical company in the United States, for the treatment of a variety of different acute and chronic pain states. As of November 2014, it is in phase III clinical trials.   Wikipedia

Chemistry

  • SMILES: CN(C)[C@@]1(CC[C@]2(CC1)OCCc3c2[nH]c4ccc(F)cc34)c5ccccc5
  • InChIKey: CSMVOZKEWSOFER-RQNOJGIXSA-N
  • Mol. Mass: 378.49
  • ALogP: 5.11
  • ChEMBL Molecule:
    cebranopadol  
More Chemistry

Pharmacology

Alternative names

6'-fluoro-4',9'-dihydro-n,n-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'h)-pyrano(3,4-b)indol)-4-amine | cebranopadol | grt6005

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

Pain

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Chronic Pain (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetic Neuropathies (Phase 2)

Heart (Phase 1)

Low Back Pain (Phase 2)

Neoplasms (Phase 3)

Osteoarthritis, Knee (Phase 2)

Pain (Phase 3)

Pain, Postoperative (Phase 2)

Pharmacokinetics (Phase 1)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue